Galapagos reports Phase IIa psoriasis data for GSK2586184

According to Galapagos N.V. (Euronext:GLPG; Pink:GLPYY), partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said twice-daily 400 mg oral GSK2586184 met the primary endpoint of a greater proportion of patients achieving a PASI 75 response at week 12 vs. placebo in the Phase IIa JAK116679 trial to treat chronic plaque psoriasis. Galapagos and GSK declined to disclose whether the twice-daily 100 and 200 mg doses of GSK2586184 met the endpoint. The double-blind, German and U.K. trial enrolled 66 patients with chronic plaque psoriasis. GSK, which conducted the trial, said it will review the complete data from all trials with GSK2586184 before determining next steps.

In February, GSK discontinued due to "lack of effect" a Phase II trial evaluating GSK2586184 to treat systemic lupus erythematosus (SLE) after the first planned interim analysis met undisclosed pre-defined stopping criteria. At the same time, the pharma also placed a Phase I/II trial for ulcerative colitis (UC) on hold. Galapagos said the UC trial remains on hold (see BioCentury Extra, Feb. 28). ...